Sanquin Home Sanquin Home Sanquin
Home ● Contact ● Sanquin ● News ● Jobs ● Sitemap ●
Diagnostic Services
 		●
Products
 		●
Research
 		●
Education & Training
 		●
Business Activities
Licensing opportunities
Sanquin offers a broad range of licensing opportunities and hybridomas.

For possibilities of licensing related to:
Current licensing opportunities

Disease & Therapy:
Personalized medicine within reach with Sanquins druglevel and immunogenicity testsPatent application P80957PC00
Autoimmune diseases: diagnostic methods to determine susceptibility and treatment efficacy WO2007073179/EP1801234
Publication: Breunis WB, van Mirre E, Geissler J, Laddach N, Wolbink G, van der Schoot E, de Haas M, de Boer M, Roos D, Kuijpers TW.
Copy number variation at the FCGR locus includes FCGR3A, FCGR2C and FCGR3B but not FCGR2A and FCGR2B. Hum Mutat. 2009; 30(5):E640-50.
Increasing the therapeutic efficacy of IgGPatent application PCT/EP2008/000373
Novel therapeutic agents for treatment of haemophilia A patients with inhibitors
Arterial trombosis, next generation therapeuticsRAG-35 & RAG-201 Cell lines with potential anti-von Willebrand factor capacities. Indications: arterial thrombosis, thrombotic thrombocytopenic purpura, von Willebrands disease, etc.
New DC cocktail with superior Th1, cytotoxic T cell and migratory efficacyWO2007078196/EP1806395

Vaccine technology; screening & detection:
Acceleration of the development of new vaccinsEP1683808 (A1)/WO2006080837 (A3)/WO2006080837 (A2)/CN101146824 (A)/CA2595727 (A1)

Gene target; molecular diagnostics:
Multiplex PCR for red blood cell antigen DNA genotyping in microarray formatsCN101027408/EP1591534/WO2005095650/
US2008050727/CA2561353/AU2005228297


« back